staurosporine aglycone has been researched along with Amyotrophic Lateral Sclerosis in 1 studies
staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turner, BJ | 1 |
| Murray, SS | 1 |
| Piccenna, LG | 1 |
| Lopes, EC | 1 |
| Kilpatrick, TJ | 1 |
| Cheema, SS | 1 |
1 other study available for staurosporine aglycone and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice.
Topics: Amino Acid Sequence; Amyotrophic Lateral Sclerosis; Animals; Blood-Brain Barrier; Carbazoles; Cell L | 2004 |